ABT vs ADI Stock Comparison

Scores Breakdown

Metric	ABT	ADI
📈 Growth	18/30	28/30
💰 Profitability	17/20	18/20
🏦 Financial Health	18/20	18/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	5/10
Overall Score	71/100	83/100

Side-by-Side Summaries

ABT Analysis	ADI Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over the eight quarters, ADI demonstrates a clear uptrend in top-line and bottom-line. Revenues rose from about $2.44B in 2024 Q4 to about $4.02B in 2026 Q3, a roughly 64% expansion. Net income to parent grew from about $478M in 2024 Q4 to about $1.34B in 2026 Q3, despite a dip in 2025 Q1, indicating improving profitability and operating leverage. The sequence shows steady quarterly progression and resilience during 2025. 💰 Margins & Cash Flow Gross margin runs in the mid-60s percent across quarters, supporting sustainable returns as revenue scales. Operating income remains robust, with healthy leverage by 2026 Q3. Cash flow from operating activities stayed positive across the period (e.g., around $1.6B in several quarters) even as investing/financing cash flows varied; free cash flow is generally supported by earnings. 🛡️ Balance Sheet & Liquidity Balance sheet is robust: Equity around $33–35B and total assets near $48B, with liabilities around $14B, implying conservative leverage. Current ratio fluctuates above 1, signaling solid liquidity. ⚠️ Key Drivers & Risks Drivers: AI/Data Center demand for precision analog ICs; automotive/industrial end markets. Risks: Semiconductor cyclicality and sensitivity to inventory/price shifts; valuation sensitivity and macro headwinds.

ABT Analysis

ADI Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over the eight quarters, ADI demonstrates a clear uptrend in top-line and bottom-line. Revenues rose from about $2.44B in 2024 Q4 to about $4.02B in 2026 Q3, a roughly 64% expansion. Net income to parent grew from about $478M in 2024 Q4 to about $1.34B in 2026 Q3, despite a dip in 2025 Q1, indicating improving profitability and operating leverage. The sequence shows steady quarterly progression and resilience during 2025.

💰 Margins & Cash Flow

Gross margin runs in the mid-60s percent across quarters, supporting sustainable returns as revenue scales. Operating income remains robust, with healthy leverage by 2026 Q3. Cash flow from operating activities stayed positive across the period (e.g., around $1.6B in several quarters) even as investing/financing cash flows varied; free cash flow is generally supported by earnings.

🛡️ Balance Sheet & Liquidity

Balance sheet is robust: Equity around $33–35B and total assets near $48B, with liabilities around $14B, implying conservative leverage. Current ratio fluctuates above 1, signaling solid liquidity.

⚠️ Key Drivers & Risks

Drivers: AI/Data Center demand for precision analog ICs; automotive/industrial end markets.
Risks: Semiconductor cyclicality and sensitivity to inventory/price shifts; valuation sensitivity and macro headwinds.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"